hotspot -WSS

hotspot

author：leisure time 2025-09-27 15:00:04 - browse：9

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： In 'major milestone,' FDA approves first cell therapy for solid tumors

explore

WSS

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Prescription digital therapeutics are key to pharma’s future

Crowdfunding for unproven stem cell procedures spreads misinformation

WATCH: Why do our ears pop?

'Screen and refer' systems are hurting patients

focus

hotspot

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Measles policy set amid Florida outbreak alarms vaccine proponents

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Weight loss drugs aren’t covered by Obamacare. That may change

Cancer drug shortages should be causing more outrage

Flagship Pioneering startup Sonata Therapeutics lays off 21

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

AstraZeneca lung cancer study comes in below expectations

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Opioid cravings were reduced by anti

Crowdfunding for unproven stem cell procedures spreads misinformation

entertainment

knowledge

explore

hotspot